secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001213900-24-065400
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal partners with Abbott for pivotal tecarfarin trial in LVAD patients
---------------------------------------------------------------------------

- Cadrenal (CVKD) and Abbott (ABT) initiate collaborative effort for tecarfarin pivotal trial in recently implanted LVAD patients.
- Tecarfarin received FDA Orphan Drug Designation in April 2024 for preventing clots in mechanical circulatory support devices.
- Only LVAD available in U.S. is Abbott's HeartMate 3; collaboration aims to improve anticoagulation outcomes.
- Prior clinical data suggest tecarfarin yields better anticoagulation quality in LVAD-relevant populations (multiple meds, renal impairment).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024065400/0001213900-24-065400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024065400/ea0210607-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-065400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer